Matinas BioPharma Holdings, Inc.

MAT9001: Prescription-Only Next Generation Omega-3

MAT9001 is our proprietary prescription-only omega-3 fatty acid-based composition under development for the treatment of cardiovascular and metabolic conditions

Learn More about MAT9001

Comparative Study Results

Enabling the Delivery of Life-Changing Medicines

Our differentiated lipid nano-crystal (LNC) drug delivery platform has the potential to address delivery issues associated with a range of molecules.

Learn More About Our LNC Platform

Mechanism of Action Video

Latest Matinas BioPharma News

Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Operational and Financial Results on March 9, 2020

Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

Matinas BioPharma Announces Closing of Public Offering of Common Stock

View All Press Releases »

Stock Snapshot

NYSE American

MTNB

Price

Change

Volume

Investor Presentation

Investor Presentation

View our latest Corporate Presentation

Download Presentation »